Our recent studies showed that activation of HER3 signaling and/or elevated expression of HER3 resulted in therapeutic resistance to trastuzumab and paclitaxel in HER2-overexpressing breast cancer cells [18, 20]. This evidence concerns the gene ERBB3 and breast carcinoma.